effect of N-acetylcysteine in the treatment of peritoneal dialysis and hemodialysis patients

comparison of the effectiveness of adding N-acetylcysteine to current standard treatment with standard treatment alone ??on improving residual renal function in chronic peritoneal and hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014071418482N1

Enrollment

Registered

2014-09-26

Start date

2014-08-17

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease stage 5. Chronic kidney disease, stage 5

Interventions

Intervention 1: Control group received only standard treatment including antihypertensive drugs, vitamin B, statin, asprin for a period of three month. Intervention 2: Intervention group received eff

Treatment - Drugs

Control group received only standard treatment including antihypertensive drugs, vitamin B, statin, asprin for a period of three month.

Intervention group received eff tab NAC 1200 mg BD other than standard treatment (including antihypertensive drugs, vitamin B, statin, asprin) for three month.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: treating with dialysis for more than 3 months ;having more than 100 mL urine in 24 hours. Exclusion Criteria: treating with dialysis for less than 3 months; having acute renal failure; being currently treated with antioxidants such as vitamins E, C.; being anuric (less than 100 mL urine in 24 hours).

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
24hr urine volume. Timepoint: days 0, 15, 30, 45, 60, 75, 90. Method of measurement: measuring 24hr urine volume with graded container.;Glomerular filtration rate (GFR). Timepoint: before study (day 0)and at the end of study (day 90). Method of measurement: 24hr urine volume test and evaluating mean of urea and creatinin clearance according to formula in the questionaire.;KT/V. Timepoint: before study (day 0) and at the end of study (day 90). Method of measurement: measuring urea before and after dialysis.	—

Measure

Time frame

24hr urine volume. Timepoint: days 0, 15, 30, 45, 60, 75, 90. Method of measurement: measuring 24hr urine volume with graded container.;Glomerular filtration rate (GFR). Timepoint: before study (day 0)and at the end of study (day 90). Method of measurement: 24hr urine volume test and evaluating mean of urea and creatinin clearance according to formula in the questionaire.;KT/V. Timepoint: before study (day 0) and at the end of study (day 90). Method of measurement: measuring urea before and after dialysis.

—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: before study and monthly till the end of the study. Method of measurement: laboratory.;Gastrointestinal complication (nausea, vomiting, diarrhea). Timepoint: patients visits. Method of measurement: asking from paitients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr mahsa abbaszadeh

Tehran University of Medical Science

mahsa.abbaszadeh@yahoo.com+98 21 6119 2679

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026